LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, will releas…
Author: Business Wire
Stanton Optical, a Leading Eye Health Provider, Opens Fourth Retail Store in New Orleans Area
NEW ORLEANS–(BUSINESS WIRE)– #EyeExam–Stanton Optical a retail brand of Now Optics, which is a leading eye health provider, announced its fourth store opening in the New Orleans market.
Zenni Launches First Collaboration with Renowned Designer Cynthia Rowley, Debuts Fashion-Forward Holiday Eyewear Collection
NOVATO, Calif.–(BUSINESS WIRE)– #Collection–Zenni today launched the Cynthia Rowley Holiday Capsule Collection – its first-ever collaboration with world-renowned designer Cynthia Rowley.
IVERIC bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK–(BUSINESS WIRE)–IVERIC bio reported that on Nov. 1, the Company granted Dr. Abraham Scaria a non-statutory stock option to purchase 300,000 shares of common stock.
Ocular Therapeutix™ To Report Third Quarter 2019 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report its th…
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution in Phase 2 Study Conducted in Japan
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Kala Pharmaceuticals to Report Third Quarter 2019 Financial Results and Host Conference Call
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Tec…
IVERIC bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12, 2019
NEW YORK–(BUSINESS WIRE)–IVERIC bio today announced that it will report its third quarter 2019 financial and operating results on Tuesday, November 12, 2019.
Minnetronix Medical Names Jeremy Maniak President and CEO
ST. PAUL, Minn.–(BUSINESS WIRE)–Minnetronix Medical, a leading medical technology company, announces appointment of Jeremy Maniak to President and CEO.
Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting
DUBLIN–(BUSINESS WIRE)–Horizon announced that clinical data for teprotumumab in the treatment of active thyroid eye disease will be presented at the ACR Annual Meeting.
Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that results of a prospective, controlled study showing that its FDA-approved ophthalmic drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% reduces use of…
NovaBay Pharmaceuticals Launches Online Sales of CelleRx® Skin Cleanser for Post-Aesthetic Dermatology and Cosmetic Surgery Procedures
EMERYVILLE, Calif.–(BUSINESS WIRE)– #NovaBay–NovaBay Pharmaceuticals launches online sales of CelleRx skin cleanser for post-aesthetic dermatology and cosmetic procedures
Global Optical Microscope Markets, 2016-2019 & Forecast to 2027 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Optical Microscope Market to 2027 – Global Analysis and Forecasts By Product, By End User, and Geography” report has been added to ResearchAndMarkets.com’s offering. The global optical microscope market is expected to reac…
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today an…
Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life
DUBLIN–(BUSINESS WIRE)–Horizon announced that integrated data for teprotumumab for the treatment of active thyroid eye disease (TED) were presented at the ATA Annual Meeting
Aldeyra Therapeutics Releases Expanded Results from Allergen Chamber Trial and Announces Plans to Initiate the Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today an…
NovaBay Pharmaceuticals to Hold Third Quarter 2019 Conference Call on November 7, 2019
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that it will report third quarter 2019 financial resu…
Resumen: La EMA y la FDA aceptan solicitudes de comercialización para satralizumab de Chugai en el trastorno del espectro de la neuromielitis óptica (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha anunciado que la Agencia Europea de Medicamentos (EMA) ha aceptado la solicitud de autorización de comercialización para satralizumab (código de desarrollo: SA237), un receptor an…